A systematic review of proton-pump inhibitor therapy for laryngopharyngeal reflux.

Abstract

The author performed a MEDLINE literature search to identify and evaluate all randomized, placebo-controlled trials of the treatment of laryngopharyngeal reflux (LPR) with an oral proton-pump inhibitor (PPI) that have been published since 1966. Eight such trials that included a total of 358 patients were identified. These eight studies contained seven different definitions of LPR. Validity scores (maximum: 9) ranged from 5 to 9 (mean: 7.5). One study investigated low-dose once-daily therapy, two studies investigated low-dose twice-daily therapy, and five studies investigated high-dose twice-daily therapy. Outcomes measures were not consistent among studies, and most studies used unvalidated outcomes measures. Only two studies found that a PPI was significantly better than placebo-one in the low-dose twice-daily group and one in the high-dose twice-daily group. The author concludes that the current body of literature is insufficient to draw reliable conclusions about the efficacy of PPI therapy for the treatment of LPR.

• Authors: Uchechukwu C Megwalu
• Journal: Ear, nose, & throat journal (Ear Nose Throat J) Vol. 92 Issue 8 Pg. 364-71 (Aug 2013) ISSN: 1942-7522 [Electronic] United States
• PMID: 23975490 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Proton Pump Inhibitors

Topics

• Humans
• Laryngopharyngeal Reflux (drug therapy)
• Proton Pump Inhibitors (administration & dosage, therapeutic use)
• Randomized Controlled Trials as Topic